tbuckley/cabot-search huggingface dataset:
Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration
Authors: Zohreh Sadat Badieyan, Taras Berezhanskyy, Maximilian Utzinger, Manish Kumar Aneja, Daniela Emrich, Reinhold Erben, Christiane Schüler, Philipp Altpeter, Mehrije Ferizi, Günther Hasenpusch, Carsten Rudolph, Christian Plank
Journal: Journal of Controlled Release (2016)
Biospecimen Complexity—the Next Challenge for Cancer Research Biobanks?
Authors: Peter H. Watson
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Biospecimens (e.g., tissues, bloods, fluids) are critical for translational cancer research to generate the necessary knowledge to guide implementation of precision medicine. Rising demand and the need for higher quality biospecimens are already evident. Experimental Design: The recent increase in requirement for biospecimen complexity in terms of linked biospecimen types, multiple preservation formats, and longitudinal data was explored by assessing trends in cancer research publications from 2000 to 2014. Results: A PubMed search shows that there has been an increase in both raw numbers and the relative proportion (adjusted for total numbers of articles in each period) of the subgroups of articles typically associated with the use of biospecimens and both dense treatment and/or outcomes data and multiple biospecimen formats. Conclusions: Increasing biospecimen complexity is a largely unrecognized and new pressure on cancer research biobanks. New approaches to cancer biospecimen resources are needed such as the implementation of more efficient and dynamic consent mechanisms, stronger participant involvement in biobank governance, development of requirements for registration of collections, and models to establish stock targets for biobanks. In particular, the latter two approaches would enable funders to establish a better balance between biospecimen supply and research demand, reduce expenditure on duplicate collections, and encourage increased efficiency of biobanks to respond to the research need for more complex cases. This in turn would also enable biobanks to focus more on quality and standardization that are surely factors in the even more important arena of research reproducibility. Clin Cancer Res; 23(4); 894–8. ©2016 AACR.
Intraperitoneal chemotherapy in pretreated ovarian cancer patients matched with patients treated with parenteral chemotherapy.
Authors: Maria Ornella Nicoletto, Alessandra Casarin, Alessandra Baldoni, Giulia Tasca, Giovanni Randon, Alessandro Cappetta, Pier Franco Conte, Simone Mocellin, Camillo Aliberti
Journal: Journal of Clinical Oncology (2016)

e17095 Background: in pretreated patients few schedule and therapy for advanced ovarian cancer Methods: This is a matched retrospective study on patients treated at the Istituto Oncologico Veneto(IOV) between January 2006 and June 2015. We queried the Gynaecological Oncology Unit database for advanced ovarian cancer patients treated with Cisplatin and/or Paclitaxel or Carboplatin (N = 33) administered through IPC; then, for each patient treated with IntraPeritoneal Chemotherapy (IPC) the database provided data from two patients treated with standard intravenous (IV) chemotherapy and matched for known prognostic factors (age, platinum sensitivity, histologic subgroup and grade). Data were then analysed for survival with nested Cox multivariate regression. Results: Upon multivariate analysis only administration route (IPC vs systemic, HR = 0.57 CI = 0.35-0.93 P = 0.024) and number of previous systemic treatments (HR = 1.87 CI = 1.44-2.43 for each incremental number of previous treatments lines, multivariate analysis, P = < .001) resulted significantly associated with survival. When analysing patients with fewer than three previous treatments lines, type of therapy was associated with a 2.2 months median survival advantage (IPC = 10 vs IV = 7.8 months, p = 0.011).The survival advantage of IPC over systemic therapy in heavily pre-treated patients (three or more previous treatments) did not result statistically significant. No patient experienced bowel occlusion and no infection as toxicity of IPC. Conclusions: Our findings confirm that IPC is an effective approach for advanced ovarian cancer even in pretreated patients as compared to systemic chemotherapy. The survival benefit appears to be confined to non-heavily pretreated patients. Overall, the direct intraperitoneal drug injection (without permanent devices) appears to be feasible, safe and possibly advantageous.
Multicenter experience with balloon mitral commissurotomy. NHLBI Balloon Valvuloplasty Registry Report on immediate and 30-day follow-up results. The National Heart, Lung, and Blood Institute Balloon Valvuloplasty Registry Participants.
Journal: Circulation (1992)

BACKGROUND Balloon mitral commissurotomy can increase mitral valve areas and reduce symptoms in selected patients with mitral stenosis. The National Heart, Lung, and Blood Institute Balloon Valvuloplasty Registry was organized to address concerns regarding differences in patient selection and technique and to report the current clinical outcome. METHODS AND RESULTS In 24 cooperating centers, 738 patients had balloon mitral commissurotomy. Baseline clinical, echo Doppler, and cardiac catheterization data, procedure details, and hemodynamic and 30-day clinical outcome were reported. Overall, 81% of the patients were women (mean age, 54 +/- 15 years), and 24% had moderate or severe other valvular lesions. When single- and double-balloon procedures were compared, the final mitral valve area was larger (1.7 +/- 0.7 versus 2.0 +/- 0.8 cm2, p = 0.0009), increase in mitral regurgitation was similar (4% versus 12%, p = 0.08), and interatrial shunts occurred more frequently (2% versus 12%, p = 0.04) after double-balloon procedures. Increase in mitral valve area was weakly related to mitral valve morphology as assessed by an echo score (r = -0.15). Multivariate predictors of improved clinical status at 30 days were cases performed in larger-volume centers, baseline mitral valve area greater than 0.5 cm2, and age less than 70 years. At 30-day follow-up, 4% of the patients with completed procedures had mitral valve surgery, 3% had died, and 83% had their overall condition improved. Patients with mixed mitral stenosis or regurgitation and isolated mitral stenosis had a similar course, but fewer patients with multivalve disease became asymptomatic. CONCLUSIONS Balloon mitral commissurotomy, as practiced in a broad range of experienced centers, produced significant short-term hemodynamic and clinical improvements. Balloon mitral commissurotomy can be considered an effective treatment option in patients with symptomatic mitral stenosis.
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Authors: Che-Hung Shen, Sun Hye Kim, Sebastian Trousil, Dennie T Frederick, Adriano Piris, Ping Yuan, Li Cai, Lei Gu, Man Li, Jung Hyun Lee, Devarati Mitra, David E Fisher, Ryan J Sullivan, Keith T Flaherty, Bin Zheng
Journal: Nature Medicine (2016)
Effect of BRCA1 gene and estrogen-receptor α on regulation of serum estradiol levels in women with breast cancer.
Authors: J. Kim, S. Lee, K. H. Oktay
Journal: Journal of Clinical Oncology (2010)

1536 Background: A BRCA1 gene mutation is well-known risk factor for breast cancer. Recently, BRCA1 gene was found to negatively regulate aromatase expression in a human granulosa cell line and also modulate estrogen-receptor α (ERα). We evaluated the estradiol (E2) levels in breast cancer patients in association with BRCA1 gene mutation and ERα status. Methods: We performed a secondary analysis of the Controlled Ovarian Stimulation Treatment with Letrozole Supplementation Study (COST-LESS, JCO 2009). Sixty-four women with breast cancer who underwent BRCA testing with known ERα status, and who were undergoing oocyte/embryo cryopreservation for fertility preservation were included. Results: The mean menstrual cycle day-2 E2 level was significantly higher in BRCA1 mutation/ERα-positive women compared to ERα and/or BRCA1 mutation negative women. Compared to BRCA1 mutation-negative women, the relative rise in E2 from baseline to the peak levels in response to ovarian stimulation was lower in BRCA1 mutation/ERα-positive women (Table). Conclusions: We speculate that under the upregulated aromatase expression in BRCA1 mutation-positive women, ERα may act as a scavenger to E2, which in turn increases E2 levels through a negative feedback. The lower relative rise of E2 in BRCA1 mutation/ERα-positive women in response to ovarian stimulation with letrozole might reflect the fact that aromatase activity is increased in this group and hence an aromatase inhibitor has a stronger effect in suppressing aromatization of androgens to estrogens. From the latter, one can speculate that aromatase inhibitors may have a stronger benefit in breast cancer treatment in BRCA1 mutation/ERα-positive women. We propose that BRCA1 gene and ERα may coregulate E2 levels in breast cancer. BRCA1 mutation (-) BRCA1 mutation (+) p value ERα (-)a(n=4) ERα (+)b(n=50) ERα (-)c(n=6) ERα (+)d(n=4) Age (years) 32.0 ± 5.7 35.5 ± 4.6 32.2 ± 4.6 32.5 ± 3.5 NS Day2 E2 (pg/mL) 31.5 ± 8.7 34.8 ± 11.9 33.4 ± 11.8 61.4 ± 21.5 d vs. a, b, c:≤0.001 Relative rise of E2 (%) (95% C.I.) 894.0(285.2∼1,502.9) 1,490.5(1,024.5∼1956.5) 1,062.8(494.8∼1630.8) 746.2(-1092.0∼2584.4) d vs. b, (a + b):0.028 No significant financial relationships to disclose.
Time to Think About Nutrient Needs in Chronic Disease
Authors: Patrick J. Stover, Robert J. Berry, Martha S. Field
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Standardization of Fractional Flow Reserve Measurements
Authors: Gabor G. Toth, Nils P. Johnson, Allen Jeremias, Mariano Pellicano, Pascal Vranckx, William F. Fearon, Emanuele Barbato, Morton J. Kern, Nico H.J. Pijls, Bernard De Bruyne
Journal: Journal of the American College of Cardiology (2016)
Risk of Concussion for Athletes in Contact Sports at Higher Altitude vs at Sea Level
Authors: Gerald S. Zavorsky, James M. Smoliga
Journal: JAMA Neurology (2016)

This meta-analysis examines the literature on concussion rates for athletes in contact sports at sea level and at a higher altitude. It has been postulated that a higher altitude increases cerebral blood flow, which causes venous blood engorgement, increases intracranial pressure, and creates subsequent slight brain swelling and a tighter fit between the brain and the skull to decrease brain sloshing and reduce concussive events. The prospect of protecting the brain from within seems novel and exciting, but the proposed physiologic basis for this mechanism is not scientifically sound. Recent studies show conflicting data on whether the incidence of sports-related concussions are associated with altitude. Thus, we sought to determine whether the incidence of concussions from contact sports is different when the sport is played at sea level vs at a higher altitude... Language: en
Use of trastuzumab associated with cisplatin and vinorelbine followed by docetaxel as a neoadjuvant regimen for patients with HER2-positive breast cancer.
Authors: G. Carillio, R. Aiello, A. Mazzola, M. Ali', G. Scandurra, E. Taibi, M. Chiarenza, G. Fallica, F. Caruso, M. Caruso
Journal: Journal of Clinical Oncology (2010)

637 Background: Some clinical trials have shown the efficacy of neoadjuvant trastuzumab in HER2- positive breast cancer patients. Cardiotoxicity is a relatively frequent side effect, particularly when the drug is associated with anthracyclines or after radiotherapy on chest wall. A reduced heart function is a major issue in young patients and may restrict the use of trastuzumab as adjuvant treatment. Methods: Since 2007 to 2009 we enrolled HER2-positive breast cancer patients into a phase II study of primary systemic therapy. The trial was designed for testing anticancer agents with proven efficacy, synergy with trastuzumab, and mild cardiotoxicity. Weekly trastuzumab was administered in combination with 6 courses of sequential chemotherapy, including 3 cycles of cisplatin 80 mg/m2 on d1 plus vinorelbine 25 mg/m2 on d1+8 q3w, followed by 3 cycles of docetaxel 100 mg/m2 q3w. Peg-filgrastim was given to prevent neutropenia and to potentiate the proposed mechanisms of action of trastuzumab, such as activation of the immune system. Surgery was performed within 5 weeks after the treatment completion. Radiation and endocrine therapy were delivered according to standard practice guidelines. One year of postoperative trastuzumab was planned too. The primary objective was the rate of pathologic complete response (pCR). Secondary end-points included safety and rate of successful breast-conserving surgery. Results: Among 31 evaluable patients, 13 and 18 of them had stage II and III tumours, respectively. Five women (16%) received a diagnosis of stage IIIB breast cancer, including two cases of tumour spreading to skin (T4b) and three cases of inflammatory carcinoma (T4d). Median age was 47 years (range 23-70). Two patients had synchronous bilateral cancers. The rate of pCR was 38% (12/31). Among 29 patients initially proposable for demolitive operation, 17 of them (58%) finally received breast-conserving surgery. Treatment was well tolerated. No case of LVEF decrease or other severe toxicities was recorded. Alopecia was only moderate. Conclusions: Trastuzumab associated with cisplatin and vinorelbine followed by docetaxel was a feasible and safe neoadjuvant regimen. No significant financial relationships to disclose.
A Nationwide Cohort Study of the Association Between Hospitalization With Infection and Risk of Death by Suicide
Authors: Helene Lund-Sørensen, Michael E. Benros, Trine Madsen, Holger J. Sørensen, William W. Eaton, Teodor T. Postolache, Merete Nordentoft, Annette Erlangsen
Journal: JAMA Psychiatry (2016)

Findings suggest that infections might be linked to the development of psychiatric disorders and suicidal behavior. Large-scale studies are needed to investigate the effect of infection on the risk of suicide.To estimate the association between hospitalization with infection and the risk of death by suicide.Nationwide, population-based, prospective cohort study with more than 149 million person-years of follow-up. Data were analyzed with survival analysis techniques and were adjusted for sex, age, calendar period, cohabitation status, socioeconomic status, and the Charlson Comorbidity Index. Individual data were drawn from Danish longitudinal registers. A total of 7.22 million individuals 15 years or older living in Denmark between January 1, 1980, and December 31, 2011, were observed during a 32-year follow-up period.The risk of death by suicide was identified in the Danish Cause of Death Register. Incidence rate ratios (IRRs) and accompanying 95% CIs were used as measures of relative risk.In 7 221 578 individuals (3 601 653 men and 3 619 925 women) observed for a total of 149 061 786 person-years, 32 683 suicides were observed during the follow-up period. Among the suicides, 7892 (24.1%) individuals had previously been diagnosed as having an infection during a hospitalization. Hospitalization with infection was linked to an elevated risk of suicide, with an IRR of 1.42 (95% CI, 1.38-1.46) compared with those without prior infection. Dose-response relationships were observed with respect to the number of hospital contacts for different infections. For example, having 7 or more infections was linked to an IRR of 2.90 (95% CI, 2.14-3.93). The number of days of treatment for infections was associated with an elevated risk of suicide in a dose-response relationship. More than 3 months of hospital treatment was linked to an IRR of 2.38 (95% CI, 2.05-2.76). The population-attributable risk associated with hospitalization with infection accounted for 10.1% of suicides.An increased risk of death by suicide was found among individuals hospitalized with infection in prospective and dose-response relationships. These findings indicate that infections may have a relevant role in the pathophysiological mechanisms of suicidal behavior.
Researchers Develop Tissue-Engineered Cartilage
Authors: Tracy Hampton
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).
Authors: Jonathon B. Cohen, Susan Geyer, Gerard Lozanski, Weiqiang Zhao, Nyla A. Heerema, Jeffrey A. Jones, Pierluigi Porcu, Beth Christian, Robert A. Baiocchi, Kami Maddocks, Joseph M. Flynn, Steven M. Devine, Kristie A. Blum
Journal: Blood (2012)
Discontinuance of Routine Smallpox Vaccination
Authors: Mahfouz H. Zaki
Journal: JAMA (1972)

<h3>To the Editor.—</h3> This letter is not intended to refute Public Health Service (PHS) recommendations which many workers in the field of preventive medicine, including myself, disagree with for several reasons, but rather to discuss flaws in our vaccination procedures. While spending my sabbatical year as Peace Corps Physician and Public Health Advisor in Afghanistan, I was faced with a situation where I had to examine the vaccination status of our volunteers and staff. The 3-year-old son of one of the Afghan employees in the Peace Corps office died of smallpox. I visited the employee's house to examine the child's body for evidence of smallpox, but the child had already been buried and he had not been seen by a physician prior to his death. The history and description of the rash, however, were suggestive of smallpox. It was safest to assume that the child died of smallpox and to
Counterfeit Medications and Fentanyl
Authors: Traci C. Green, Michael Gilbert
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Some Biological Aspects of the Factor in Bone Marrow Responsible for Hematopoietic Recovery Following Systemic Irradiation&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;3&lt;/xref&gt;
Authors: M.B. Brown, B.B. Hirsch, C.S. Nagareda, S.K. Hochstetler, W.G. Faraghan, P. Toch, H.S. Kaplan
Journal: JNCI Journal of the National Cancer Institute (1955)

Some Biological Aspects of the Factor in Bone Marrow Responsible for Hematopoietic Recovery Following Systemic Irradiation Get access Mary B. Brown, Mary B. Brown Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Barbara B. Hirsch, Barbara B. Hirsch Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar C. Susan Nagareda, C. Susan Nagareda Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Sarah K. Hochstetler, Sarah K. Hochstetler Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar William G. Faraghan, William G. Faraghan Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul Toch, Paul Toch Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Henry S. Kaplan Henry S. Kaplan Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 4, February 1955, Pages 949–973, https://doi.org/10.1093/jnci/15.4.949 Published: 01 February 1955 Article history Received: 27 October 1954 Published: 01 February 1955